Antifungal drug tested against brain tumors – trial stopped early

NCT ID NCT03796273

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested whether the antifungal drug ketoconazole could block a protein called tGLI1 in brain tumors. It included 15 people with breast cancer that spread to the brain or with a type of brain cancer called glioma. The study was terminated early, so we have limited information on whether the drug worked or was safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ketoconazole

What this could lead to

If it had worked, this could have pointed toward a new way to treat brain tumors by targeting a specific protein.

What could go wrong

This was a very early, small trial that was terminated before completion, so we don't have enough data to know if it works or is safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma (excluding glioblastoma) breast cancer glioma invasive breast carcinoma metastatic malignant neoplasm in the brain metastatic neoplasm oligodendroglioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina, 27157, United States